South Korea · Delayed Price · Currency is KRW L&C BIO Co.,LTD Statistics
Total Valuation
L&C BIO Co.,LTD has a market cap or net worth of KRW 1.09 trillion. The enterprise value is 1.12 trillion.
| Market Cap | 1.09T |
| Enterprise Value | 1.12T |
Important Dates
The next estimated earnings date is Wednesday, February 17, 2027.
| Earnings Date | Feb 17, 2027 |
| Ex-Dividend Date | Dec 29, 2026 |
Share Statistics
L&C BIO Co.,LTD has 53.94 million shares outstanding. The number of shares has increased by 9.08% in one year.
| Current Share Class | 53.94M |
| Shares Outstanding | 53.94M |
| Shares Change (YoY) | +9.08% |
| Shares Change (QoQ) | +6.36% |
| Owned by Insiders (%) | 20.91% |
| Owned by Institutions (%) | 13.05% |
| Float | 38.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 13.70 |
| PS Ratio | 9.35 |
| PB Ratio | 3.24 |
| P/TBV Ratio | 5.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 41.63 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 9.63 |
| EV / EBITDA | 41.20 |
| EV / EBIT | 61.58 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.33, with a Debt / Equity ratio of 0.19.
| Current Ratio | 1.33 |
| Quick Ratio | 0.58 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 2.33 |
| Debt / FCF | n/a |
| Interest Coverage | 2.75 |
Financial Efficiency
Return on equity (ROE) is -45.32% and return on invested capital (ROIC) is 6.05%.
| Return on Equity (ROE) | -45.32% |
| Return on Assets (ROA) | 2.38% |
| Return on Invested Capital (ROIC) | 6.05% |
| Return on Capital Employed (ROCE) | 5.31% |
| Weighted Average Cost of Capital (WACC) | 12.20% |
| Revenue Per Employee | 635.54M |
| Profits Per Employee | -816.46M |
| Employee Count | 183 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 1.12 |
Taxes
| Income Tax | -227.76M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.72% in the last 52 weeks. The beta is 1.49, so L&C BIO Co.,LTD's price volatility has been higher than the market average.
| Beta (5Y) | 1.49 |
| 52-Week Price Change | -19.72% |
| 50-Day Moving Average | 25,689.00 |
| 200-Day Moving Average | 33,712.38 |
| Relative Strength Index (RSI) | 33.52 |
| Average Volume (20 Days) | 456,831 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, L&C BIO Co.,LTD had revenue of KRW 116.30 billion and -149.41 billion in losses. Loss per share was -2,990.48.
| Revenue | 116.30B |
| Gross Profit | 68.23B |
| Operating Income | 18.43B |
| Pretax Income | -149.48B |
| Net Income | -149.41B |
| EBITDA | 27.42B |
| EBIT | 18.43B |
| Loss Per Share | -2,990.48 |
Balance Sheet
The company has 41.53 billion in cash and 63.77 billion in debt, with a net cash position of -22.23 billion or -412.19 per share.
| Cash & Cash Equivalents | 41.53B |
| Total Debt | 63.77B |
| Net Cash | -22.23B |
| Net Cash Per Share | -412.19 |
| Equity (Book Value) | 335.19B |
| Book Value Per Share | 6,077.25 |
| Working Capital | 42.77B |
Cash Flow
In the last 12 months, operating cash flow was 26.11 billion and capital expenditures -29.98 billion, giving a free cash flow of -3.88 billion.
| Operating Cash Flow | 26.11B |
| Capital Expenditures | -29.98B |
| Depreciation & Amortization | 8.99B |
| Net Borrowing | -12.55B |
| Free Cash Flow | -3.88B |
| FCF Per Share | -71.84 |
Margins
Gross margin is 58.67%, with operating and profit margins of 15.85% and -128.47%.
| Gross Margin | 58.67% |
| Operating Margin | 15.85% |
| Pretax Margin | -128.53% |
| Profit Margin | -128.47% |
| EBITDA Margin | 23.58% |
| EBIT Margin | 15.85% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 25.00, which amounts to a dividend yield of 0.12%.
| Dividend Per Share | 25.00 |
| Dividend Yield | 0.12% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.08% |
| Shareholder Yield | -8.96% |
| Earnings Yield | -14.84% |
| FCF Yield | -0.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for L&C BIO Co.,LTD is 36,000.00, which is 78.66% higher than the current price. The consensus rating is "Buy".
| Price Target | 36,000.00 |
| Price Target Difference | 78.66% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 50.68% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on October 26, 2026. It was a forward split with a ratio of 2.
| Last Split Date | Oct 26, 2026 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
L&C BIO Co.,LTD has an Altman Z-Score of 7.14 and a Piotroski F-Score of 7.
| Altman Z-Score | 7.14 |
| Piotroski F-Score | 7 |